248 related articles for article (PubMed ID: 30121698)
1. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata.
Guttman-Yassky E; Nia JK; Hashim PW; Mansouri Y; Alia E; Taliercio M; Desai PN; Lebwohl MG
Arch Dermatol Res; 2018 Oct; 310(8):607-614. PubMed ID: 30121698
[TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study.
Narang T; Daroach M; Kumaran MS
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133875
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H
Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933
[TBL] [Abstract][Full Text] [Related]
5. Use of adapalene in alopecia areata: Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata.
Unal M
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193637
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous efalizumab is not effective in the treatment of alopecia areata.
Price VH; Hordinsky MK; Olsen EA; Roberts JL; Siegfried EC; Rafal ES; Korman NJ; Altrabulsi B; Leung HM; Garovoy MR; Caro I; Whiting DA
J Am Acad Dermatol; 2008 Mar; 58(3):395-402. PubMed ID: 18280336
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
9. Topical Calcipotriol Therapy for Mild-to-Moderate Alopecia Areata: A Retrospective Study.
Çerman AA; Solak SS; Altunay İ; Küçükünal NA
J Drugs Dermatol; 2015 Jun; 14(6):616-20. PubMed ID: 26091388
[TBL] [Abstract][Full Text] [Related]
10. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
Chua SH; Goh CL; Ang CB
Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
[TBL] [Abstract][Full Text] [Related]
11. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study.
Farshi S; Mansouri P; Safar F; Khiabanloo SR
Int J Dermatol; 2010 Oct; 49(10):1188-93. PubMed ID: 20883409
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy.
Morsy H; Maher R; Negm D
J Cosmet Dermatol; 2018 Jun; 17(3):533-537. PubMed ID: 29707896
[TBL] [Abstract][Full Text] [Related]
13. Alopecia areata predictive score: A new trichoscopy-based tool to predict treatment outcome in patients with patchy alopecia areata.
Waśkiel-Burnat A; Rakowska A; Sikora M; Olszewska M; Rudnicka L
J Cosmet Dermatol; 2020 Mar; 19(3):746-751. PubMed ID: 31301100
[TBL] [Abstract][Full Text] [Related]
14. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation.
El Taieb MA; Ibrahim H; Nada EA; Seif Al-Din M
Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27791311
[TBL] [Abstract][Full Text] [Related]
15. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study.
Strober BE; Siu K; Alexis AF; Kim G; Washenik K; Sinha A; Shupack JL
J Am Acad Dermatol; 2005 Jun; 52(6):1082-4. PubMed ID: 15928633
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
17. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E; Renert-Yuval Y; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Garcet S; Pavel AB; Lebwohl MG; Krueger JG
Allergy; 2022 Mar; 77(3):897-906. PubMed ID: 34460948
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
19. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
20. The role of fractional laser-assisted drug delivery in enhancing the efficacy of topical bimatoprost solution in the treatment of alopecia areata: An intra-patient comparative randomized clinical trial.
Meymandi SS; Safari A; Meymandi MS; Aflatoonian M
J Cosmet Dermatol; 2024 May; 23(5):1663-1668. PubMed ID: 38321929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
